Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism.
Sijin HangHui ChenWen-Hui WuShiyi WangYiwen FangRuilong ShengQidong TuRuihua GuoPublished in: Marine drugs (2022)
Compound 1 (SMTP-7, also FGFC1), an isoindolone alkaloid from marine fungi Starchbotrys longispora FG216 and fungi Stachybotrys microspora IFO 30018, possessed diverse bioactivities such as thrombolysis, anti-inflammatory and anti-oxidative properties, and so on. It may be widely used for the treatment of various diseases, including cerebral infarction, stroke, ischemia/reperfusion damage, acute kidney injury, etc. Especially in cerebral infarction, compound 1 could reduce hemorrhagic transformation along with thrombolytic therapy, as the traditional therapies are accompanied with bleeding risks. In the latest studies, compound 1 selectively inhibited the growth of NSCLC cells with EGFR mutation, thus demonstrating its excellent anti-cancer activity. Herein, we summarized pharmacological activities, preparation of staplabin congeners-especially compound 1 -and the mechanism of compound 1, with potential therapeutic applications.
Keyphrases
- acute kidney injury
- small cell lung cancer
- pulmonary embolism
- atrial fibrillation
- anti inflammatory
- induced apoptosis
- oxidative stress
- cardiac surgery
- epidermal growth factor receptor
- risk assessment
- tyrosine kinase
- mass spectrometry
- cell proliferation
- human health
- subarachnoid hemorrhage
- brain injury
- climate change
- liquid chromatography